Skip to content

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

 
  • En
  • Sv
  • About us
    • Management
    • Board of Directors
  • Therapeutic areas
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Orviglance®
    • Oncoral
  • Partnering
  • Investors
    • Press releases
    • Financial reports
    • Presentations & articles
    • Events
    • Share information
    • Shareholders
    • Insiders
    • Equity research
    • Financial calendar
  • Governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Our values
  • Contact
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Subscribe to press releases
All All press releasesRegulatory press releasesFinancial reports
Regulatory
2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral
PDF
Report
Presentation
Webcast
Regulatory
2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent
PDF
Report
Presentation
Webcast
Regulatory
2020-11-05 | Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch
PDF
Report
Presentation
Webcast
2020-11-03 | EMA confirms Mangoral eligible for the centralized regulatory procedure in the EU
PDF
Report
Presentation
Webcast
Regulatory
2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually
PDF
Report
Presentation
Webcast
2020-09-30 | Invitation to Ascelia Pharma’s virtual Capital Markets Day
PDF
Report
Presentation
Webcast
2020-09-18 | First commercial scale manufacturing of Mangoral
PDF
Report
Presentation
Webcast
Regulatory
2020-08-20 | Quarterly Report Q2-2020: First participant in the hepatic study
PDF
Report
Presentation
Webcast
Regulatory
2020-07-31 | Change in number of shares and votes in Ascelia Pharma AB
PDF
Report
Presentation
Webcast
Regulatory
2020-06-30 | Ascelia Pharma completes a directed new share issue of 4,697,781 shares, raising approximately SEK 98.7 million
PDF
Report
Presentation
Webcast
2020-06-09 | Presentation of Ascelia Pharma at ABGSC Life Science Summit Day and Redeye Orphan Drug Day
PDF
Report
Presentation
Webcast
2020-05-26 | Vator Securities: Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged.
PDF
Report
Presentation
Webcast
Regulatory
2020-05-20 | Updated SPARKLE timelines due to Covid-19 impact
PDF
Report
Presentation
Webcast
Regulatory
2020-05-13 | Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE
PDF
Report
Presentation
Webcast
Regulatory
2020-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2020
PDF
Report
Presentation
Webcast
Regulatory
2020-05-06 | First participant enrolled in the clinical hepatic impairment study with Mangoral
PDF
Report
Presentation
Webcast
2020-04-16 | Patent for Oncoral approved in Japan
PDF
Report
Presentation
Webcast
Regulatory
2020-04-06 | Ascelia Pharma publishes Annual Report for the financial year 2019
PDF
Report
Presentation
Webcast

Posts navigation

Older posts
Learn more

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. […]
Learn more

Contact

Ascelia Pharma’s Annual Report for the financial year 2019 has today been published on the company’s website www.ascelia.com For further information, please contact: Mikael Widell, Head of IR & Communications Email: mw@ascelia.com Tel: +46 703 11 99 60 This information is such information as Ascelia Pharma is obliged to make public pursuant t ...
Learn more

Our values

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical […]
  1. Start (en)

About us

  • Start (en)
  • About us
  • Career
  • Contact
  • Privacy policy
  • About cookies
  • Cookie settings
  • IMPORTANT INFORMATION

Pipeline

  • Oncoral
  • Orviglance®

IR & Media

  • Subscribe to press releases
  • Press releases & News
  • Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Follow us

 

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

© Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance.

Video
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all